Aragen Life Sciences, a leading contract research, development and manufacturing organisation, has announced the signing of a strategic Memorandum of Understanding with Thermo Fisher Scientific to integrate Gibco cell culture media with Aragen’s end to end CRDMO capabilities.

This collaboration brings together high performance, well characterised Gibco cell culture media with Aragen’s deep expertise across process development, scale up, and GMP manufacturing. The partnership is designed to optimise upstream bioprocess development by ensuring a stronger alignment between media selection and process performance.

By streamlining the media process fit and reducing variability, the collaboration aims to deliver more robust and reproducible manufacturing processes. It is expected to accelerate technology transfer timelines and enhance overall productivity, enabling faster progression of biologics and biosimilars from early stage development through to commercial manufacturing.

A spokesperson from Aragen Life Sciences said, “This partnership reflects our continued commitment to delivering integrated, science led solutions that support our clients across the entire development lifecycle. By combining proven media systems with our process expertise, we can help improve efficiency, scalability, and speed to market.”

A representative from Thermo Fisher Scientific added, “Collaborating with Aragen allows us to extend the value of our Gibco cell culture solutions within a highly capable CRDMO environment. Together, we aim to support customers in achieving consistent, high quality outcomes in biologics manufacturing.”

The partnership reinforces both organisations’ focus on enabling innovation in biologics development, addressing increasing industry demand for scalable, efficient, and reliable manufacturing solutions.